Premium
Development and clinical use of the new gastrointestinal prokinetic drug cisapride (R 51 619)
Author(s) -
Reyntjens André,
Verlinden Marleen,
Aerts Tonny
Publication year - 1986
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430080130
Subject(s) - cisapride , gastroparesis , metoclopramide , prokinetic agent , mosapride , medicine , gastroenterology , drug , pharmacology , constipation , muscarinic acetylcholine receptor , gastric emptying , stomach , receptor , vomiting
Cisapride is a new gastrointestinal prokinetic substance that is devoid of antidopaminergic and direct muscarinic activity. This was evidenced by a lack of effect on prolactin release and gastric secretion. In man, cisapride stimulates lower esophageal, gastric, small intestinal, and colonic motility. Accordingly, cisapride significantly improves esophageal reflux disorders, gastroparesis, and constipation and has been successfully used in the treatment of clinical conditions that result from a deficient motor coordination.